Last reviewed · How we verify
A Randomized Phase III Study to Compare Conventional Chemotherapy (CHOEP-14) + Rituximab vs High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation (Mega-CHOEP-21) + Rituximab in Younger Patients With Aggressive NHL
According to amendment 3 this study addresses the question if intensification of administration of rituximab in standard treatment for patients with newly diagnosed aggressive B-Non Hodgkin Lymphoma (B-NHL) and high risk (aaIPI 2 or 3) results in a better time to treatment failure (TTTF)
Details
| Lead sponsor | German High-Grade Non-Hodgkin's Lymphoma Study Group |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 450 |
| Start date | 2003-03 |
| Completion | 2017-10 |
Conditions
- Non-Hodgkin's Lymphoma (NHL)
Interventions
- R-CHOEP 14 with 12x Rituximab
Primary outcomes
- time to treatment failure — 3 years after study inclusion
At 3 year follow up rate of treatments and time to treatment failure will be determined
Countries
Germany